Hasil Pencarian - María Vieito

  • Menampilkan 1 - 8 hasil dari 8
Perbaiki Hasil
  1. 1
    Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel–Lindau-Disease-Associated Tumors

    Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel–Lindau-Disease-Associated Tumors oleh Cristina Suárez, Maria Vieito, Augusto Valdivia, Macarena González, Joan Carles

    Diterbitkan 2023-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back

    Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back oleh Luis León-Mateos, María Vieito, Urbano Anido, Rafael López López, Laura Muinelo Romay

    Diterbitkan 2016-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Molecular characterization of circulating tumor cells in human metastatic colorectal cancer.

    Molecular characterization of circulating tumor cells in human metastatic colorectal cancer. oleh Jorge Barbazán, Lorena Alonso-Alconada, Laura Muinelo-Romay, María Vieito, Alicia Abalo, Marta Alonso-Nocelo, Sonia Candamio, Elena Gallardo, Beatriz Fernández, Ihab Abdulkader, María de Los Ángeles Casares, Antonio Gómez-Tato, Rafael López-López, Miguel Abal

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

    First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors oleh Rebecca Kristeleit, Juan Martin-Liberal, Kristen Spencer, Janice M Mehnert, Maria Vieito, Elizabeth J Davis, Angela Orcurto, Thomas Condamine, Daniel C Cho, Jennifer Pulini, Rowan E Miller, Sarah P Blagden, Dominik Berthold, Dana B Cardin, Prashanth Hari Dass, John E Janik, Jason Clark, Xuejun Chen

    Diterbitkan 2022-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study

    Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid... oleh Joaquina C. Baranda, Debbie Robbrecht, Ryan Sullivan, Bernard Doger, Armando Santoro, Minal Barve, Jean‐Jacques Grob, Oliver Bechter, Maria Vieito, Maria Jose deMiguel, Dirk Schadendorf, Melissa Johnson, Clemence Pouzin, Cathy Cantalloube, Rui Wang, Jooyun Lee, Xiaofei Chen, Brigitte Demers, Amele Amrate, Giovanni Abbadessa, F. Stephen Hodi

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas

    BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas oleh Victor Moreno, Maria Vieito, Juan Manuel Sepulveda, Vladimir Galvao, Tatiana Hernández-Guerrero, Bernard Doger, Omar Saavedra, Carmelo Carlo-Stella, Jean-Marie Michot, Antoine Italiano, Massimo Magagnoli, Cecilia Carpio, Antonio Pinto, Rafael Sarmiento, Barbara Amoroso, Ida Aronchik, Ellen Filvaroff, Bishoy Hanna, Xin Wei, Zariana Nikolova, Irene Braña

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    638 Characterisation of the immune response to EO2401, a new immunotherapy approach against cancer, plus nivolumab in recurrent glioblastoma: The EOGBM1–18/ROSALIE study

    638 Characterisation of the immune response to EO2401, a new immunotherapy approach against cancer, plus nivolumab in recurrent glioblastoma: The EOGBM1–18/ROSALIE study oleh Agostina Stradella, Francois Ghiringhelli, Ana Maia, Macarena Gonzalez, Cécile Gouttefangeas, Ulrich Herrlinger, David Reardon, Ahmed Idbaih, Patrick Wen, Ghazaleh Tabatabai, Wolfgang Wick, Mirjam Renovanz, Maria Vieito Villar, Christophe Bonny, Joao Gamelas Magalhaes, Hélène Toussaint, Jean-Michel Paillarse, Marta GilMartin, Iris Mildenberger, Michael C Burger, Alice Hervieu, Mehdi Touat, Antje Wick

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy

    LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy oleh Mónica Pascual-García, Ester Bonfill-Teixidor, Ester Planas-Rigol, Carlota Rubio-Perez, Raffaella Iurlaro, Alexandra Arias, Isabel Cuartas, Ada Sala-Hojman, Laura Escudero, Francisco Martínez-Ricarte, Isabel Huber-Ruano, Paolo Nuciforo, Leire Pedrosa, Carolina Marques, Irene Braña, Elena Garralda, María Vieito, Massimo Squatrito, Estela Pineda, Francesc Graus, Carmen Espejo, Juan Sahuquillo, Josep Tabernero, Joan Seoane

    Diterbitkan 2019-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: